Related Experiment Video
Updated: Feb 1, 2026
Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing
Hong Gao1, Yuhong Duan2, Xiaoxu Fu1
1Teaching Hospital, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Insights
SHENQI compound offers a more comprehensive treatment for diabetic vasculopathy than rosiglitazone, significantly inhibiting vascular lesions. Rosiglitazone effectively lowers blood glucose but has a lesser impact on vascular complications.
Area of Science:
- Pharmacology
- Diabetology
- Vascular Biology
Background:
- Diabetic vasculopathy, a major complication of diabetes, leads to significant morbidity and mortality.
- Traditional Chinese Medicine (TCM) SHENQI compound and Western medicine rosiglitazone are used for diabetes treatment.
- SHENQI compound shows promise in inhibiting vascular lesions associated with diabetes.
Purpose of the Study:
- To compare the therapeutic mechanisms and efficacy of SHENQI compound and rosiglitazone in treating diabetic vasculopathy.
- To elucidate the molecular pathways and identify key regulators involved in the treatment effects.
- To provide theoretical guidance for clinicians and drug designers.
Main Methods:
- Establishment of 7 groups of mouse models for diabetic vasculopathy.
- Assessment of behavioral, physiological, and pathological characteristics.
- Differential gene expression analysis and functional enrichment analysis of differentially expressed genes (DEGs).
- Pivot regulator analysis to identify key therapeutic targets.
Main Results:
- SHENQI compound demonstrated a more comprehensive therapeutic effect and stronger inhibition of vascular lesions compared to rosiglitazone.
- Rosiglitazone showed effective hypoglycemic effects but no significant impact on vascular lesions.
- SHENQI compound regulates MCM8, IRF7, CDK7, NEDD4L; rosiglitazone targets PSMD3, UBA52 for glucose regulation.
- Identification of pivot transcription factors (TFs) and non-coding RNAs (ncRNAs) mediating drug effects.
Conclusions:
- SHENQI compound offers superior and broader therapeutic benefits for diabetic vasculopathy than rosiglitazone.
- Distinct molecular targets and pathways are modulated by each treatment, highlighting differential mechanisms of action.
- The study identifies potential therapeutic targets and mediators, offering valuable insights for future drug development in diabetic vasculopathy.
Abstract:
Atherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in the treatment of diabetes. In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. The behavioral, physiological and pathological morphological characteristics of these mice showed that SHENQI compound has a more comprehensive curative effect than rosiglitazone and has a stronger inhibitory effect on vascular lesions. While rosiglitazone has a more effective but no significant effect on hypoglycemic. Further, based on the gene expression of mice in each group, we performed differential expression analysis. The functional enrichment analysis of these differentially expressed genes (DEGs) revealed the potential pathogenesis and treatment mechanisms of diabetic angiopathy. In addition, we found that SHENQI compound mainly exerts comprehensive effects by regulating MCM8, IRF7, CDK7, NEDD4L by pivot regulator analysis, while rosiglitazone can rapidly lower blood glucose levels by targeting PSMD3, UBA52. Except that, we also identified some pivot TFs and ncRNAs for these potential disease-causing DEG modules, which may the mediators bridging drugs and modules. Finally, similar to pivot regulator analysis, we also identified the regulation of some drugs (e.g. bumetanide, disopyramide and glyburide etc.) which have been shown to have a certain effect on diabetes or diabetic angiopathy, proofing the scientific and objectivity of this study. Overall, this study not only provides an in-depth comparison of the efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy, but also provides clinicians and drug designers with valuable theoretical guidance.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:22Alzheimer's Disease: Treatment
04:01Factors Affecting Solubility
02:16Transcription Factors
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...